The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ivanets N.N.

Sechenov First Moscow State Medical University (Sechenov University)

Kinkulkina M.A.

Sechenov First Moscow State Medical University (Sechenov University)

Tikhonova Yu.G.

Sechenov First Moscow State Medical University (Sechenov University)

Avdeeva T.I.

Sechenov First Moscow State Medical University (Sechenov University)

Ragimov A.A.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Dashkova N.G.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Kuznetsov O.E.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Matveev A.V.

National Pharmacovigilance Research Center;
Medical Academy n. a. S.I. Georgievsky of Vernadskjy CFU, Simferopol

Izyumina T.A.

Sechenov First Moscow State Medical University (Sechenov University)

Orlov S.V.

Acad. I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

The association between the 5-HTTLPR polymorphism of the serotonin transporter gene and the efficacy and tolerability of selective serotonin reuptake inhibitors

Authors:

Ivanets N.N., Kinkulkina M.A., Tikhonova Yu.G., Avdeeva T.I., Ragimov A.A., Dashkova N.G., Kuznetsov O.E., Matveev A.V., Izyumina T.A., Orlov S.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2): 46‑51

DOI: 10.17116/jnevro20161162146-51

Read: 5102 times

Download PDF (RU)
Contact the author
Table of contents

THE ASSOCIATION BETWEEN THE 5-HTTLPR POLYMORPHISM OF THE SEROTONIN TRANSPORTER GENE AND THE EFFICACY AND TOLERABILITY OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
THE ASSOCIATION BETWEEN THE 5-HTTLPR POLYMORPHISM OF THE SEROTONIN TRANSPORTER GENE AND THE EFFICACY AND TOLERABILITY OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS

To cite this article:

Ivanets NN, Kinkulkina MA, Tikhonova YuG, et al. The association between the 5-HTTLPR polymorphism of the serotonin transporter gene and the efficacy and tolerability of selective serotonin reuptake inhibitors. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2):46‑51. (In Russ.)
https://doi.org/10.17116/jnevro20161162146-51

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The state of mental health of migrant workers and citi­zens of the Russian Fede­ration: A comparative analysis as illu­strated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101
Factors of depression acco­rding to acti­graphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32
Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55
Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107
Inve­stigation of the rela­tionship of indi­vidual characteristics of the brain bioelectrical acti­vity with levels of mental stress, aggression, anxiety, and depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):108-117
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Vali­dation of the Snaith—Hamilton Pleasure Scale to assess anhe­donia in patients with unipolar depression In Russia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):110-121
Gender characteristics of cardiovascular diseases psychosocial risk factors asso­ciations with sleep quality in an open urban popu­lation. Russian Journal of Preventive Medi­cine. 2025;(6):67-73
Dysfunctional pelvic pain in women. Russian Journal of Pain. 2025;(2):32-37
Neuropathic pain in chro­nic inflammatory demye­linating poly­neuropathies: analysis of 64 cases. Russian Journal of Pain. 2025;(2):45-53
Abstract:

OBJECTIVE

To search for the association between the 5-HTTLPR polymorphism of the serotonin transporter gene and the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs).

MATERIAL AND METHODS

The complex clinical/psychopathological and genetic study of 38 patients with depression treated with SSRIs was carried out.

RESULTS AND CONCLUSION

The 5-HTTLPR polymorphism was associated with the rate of achievement of remission and tolerability of treatment: carriers of the SS genotype achieved remission less frequently and more frequently experienced side-effects.

Keywords:

pharmacogenetics
depression
antidepressants
5-HTTLPR
serotonin reuptake

Authors:

Ivanets N.N.

Sechenov First Moscow State Medical University (Sechenov University)

Kinkulkina M.A.

Sechenov First Moscow State Medical University (Sechenov University)

Tikhonova Yu.G.

Sechenov First Moscow State Medical University (Sechenov University)

Avdeeva T.I.

Sechenov First Moscow State Medical University (Sechenov University)

Ragimov A.A.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Dashkova N.G.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Kuznetsov O.E.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Matveev A.V.

National Pharmacovigilance Research Center;
Medical Academy n. a. S.I. Georgievsky of Vernadskjy CFU, Simferopol

Izyumina T.A.

Sechenov First Moscow State Medical University (Sechenov University)

Orlov S.V.

Acad. I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Close metadata

References:

  1. Draft clinical guidelines: Recurrent Depressive Disorder. (In Russ.) https://psychiatr.ru/news/164
  2. Kostyukova EG, Gorodnichev AV. Present-day therapy for recurrent depressive disorder: from research to clinical practice. From the book «Biological therapies of mental disorders (evidence-based medicine for clinical practice), ed. SN Mosolov, Moscow: Publisher «Social and Political Thought», 2012;251-272. 
  3. Brambilla P et al. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005;38:69-77.  https://doi.org/10.1055/s-2005-837806
  4. Sghendo L, Mifsud J. Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model. Journal of Pharmacy and Pharmacology. 64:317-325.  https://doi.org/10.1111/j.2042-7158.2011.01384.x
  5. Tanti A, Belzung C. Open questions in current models of antidepressant action. British Journal of Pharmacology. 2010;159:1187-1200. https://doi.org/10.1111/j.1476-5381.2009.00585.x
  6. Mosolov SN. Biological mechanisms of recurrent depression and antidepressants. From the book «Biological therapies of mental disorders (evidence-based medicine for clinical practice), ed. SN Mosolov, Moscow: Publisher «Social and Political Thought». 2012;273-305. 
  7. Hariri AR, Weinberger DR. Functional neuroimaging of genetic variation in serotonergic neurotransmission. Genes, Brain and Behavior. 2003;2:341-349.  https://doi.org/10.1046/j.1601-1848.2003.00048.x
  8. Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry. 1997;2:457-462.  https://doi.org/10.1038/sj.mp.4000334
  9. Odgerel Z, Talati A, Hamilton SP, Levinson DF, Weissman MM. Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European- and African-American subjects from the National Institute of Mental Health’s Collaborative Center for Genomic Studies. Transl Psychiatry. 2013;3(9):307.  https://doi.org/10.1038/tp.2013.80
  10. Serretti A, Calati R, Mandelli L et al. Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets. 2006;7:1659-1669. https://doi.org/10.2174/138945006779025419
  11. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527-1531. https://doi.org/10.1126/science.274.5292.1527
  12. Little KY, McLaughlin DP, Zhang L, Livermore CS, Dalack GW, De McFinton PRI, Proposto ZS, Hill E, Cassin BJ, Watson SJ, Cook EH. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry. 1998;155:207-213. 
  13. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry. 2000;47:643-649.  https://doi.org/10.1016/s0006-3223(99)00171-7
  14. Naylor L, Dean B, Pereira A, Mackinnon A, Kouzmenko A, Copolov D. No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus. Mol Med. 1998;4:671-674. 
  15. Mann JJ, Huang Y-Y, Underwood M, Kassir SA, Oppenheim S, Kelly TM, Dwork AJ, Arango V. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontalcortical binding in major depression and suicide. Arch Gen Psychiatry. 2000;57:729-738.  https://doi.org/10.1001/archpsyc.57.8.729
  16. Kaiser R, Muller-Oerlinghausen B, Filler D, Tremblay P-B, Berghofer A, Roots I, Brockmoller J. Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. Am J Med Genet. 2002;114:323-328.  https://doi.org/10.1002/ajmg.10119
  17. Serretti A, Kato M, De Ronchi D et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12:247-257.  https://doi.org/10.1038/sj.mp.4001926
  18. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22(4):239-258.  https://doi.org/10.1016/j.euroneuro.2011.10.003
  19. Smits K, Smits L, Peeters F, Schouten J, Janssen R, Smeets H, van Os J, Prins M. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 2007;22(3):137-143.  https://doi.org/10.1097/yic.0b013e328014822a
  20. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, Rosenbaum JF, Fava M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry. 2003;54(9):879-883.  https://doi.org/10.1016/s0006-3223(03)00424-4
  21. Ferreira Ade A, Neves FS, da Rocha FF et al. The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder. J Affect Disord. 2009;112(1-3):267-272.  https://doi.org/10.1016/j.jad.2008.04.012
  22. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163-1169. https://doi.org/10.1001/archpsyc.61.11.1163
  23. Popp J, Leucht S, Heres S, Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy — a pilot study. Pharmacogenomics. 7:2:159-166.  https://doi.org/10.2217/14622416.7.2.159
  24. Lanctôt KL, Rapoport MJ, Chan F et al. Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. Brain Inj. 2010;24(7-8):959-969.  https://doi.org/10.3109/02699051003789229
  25. Hodgson K, Uher R, Crawford AA, Lewis G, O’Donovan MC, Keers R, Dernovsek MZ, Mors O, Hauser J, Souery D, Maier W, Henigsberg N, Rietschel M, Placentino A, Aitchison K, Farmer A, Davis O, McGuffin P. Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) Study. J Psychopharmacol. 2014;28(2):142-150.  https://doi.org/10.1177/0269881113517957
  26. Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol. 2013;28(5):516-522.  https://doi.org/10.1002/hup.2340
  27. Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry. 2011;12(7):501-515.  https://doi.org//10.3109/15622975.2011.572998
  28. Rebrova O. Statistical analysis of medical data. The use of software package Statistica. M.: Mediasphere; 2002.
  29. Blier P. Neurotransmitter targeting in the treatment of depression. J Clin Psychiatry. 2013;74(suppl 2):19-24.  https://doi.org/10.4088/jcp.12084su1c.04
  30. Outhred T, Hawkshead BE, Wager TD, Das P, Malhi GS, Kemp AH. Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: Implications for differential treatment efficacy. Neurosci Biobehav Rev. 2013;37(8):1786-1800. https://doi.org/10.1016/j.neubiorev.2013.07.010
  31. Hunter AM, Leuchter AF, Morgan ML et al. Neurophysiologic correlates of the Side Effects in Normal Subjects Randomized to Venlafaxine or Placebo. Neuropsychopharmacol. 2005;30(4):792-799.  https://doi.org/10.1038/sj.npp.1300652
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.